

# CITATION REPORT

List of articles citing

**A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008**

**DOI: 10.1002/cncr.22117**  
**Cancer, 2006, 107, 1273-9.**

**Source:** <https://exaly.com/paper-pdf/40857205/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
65	Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5 Suppl 1, S31-9	3.3	4
64	Recent advances in the therapy of renal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 233-42	5.4	6
63	Integrated therapy of kidney cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18 Suppl 6, vi141-8	10.3	24
62	Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 817-20	2.4	9
61	Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC). <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 780-6	5	6
60	Renal cell carcinoma: current status and emerging therapies. <i>Cancer Treatment Reviews</i> , <b>2007</b> , 33, 299-314	11.4	74
59	A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 689-94	3.5	24
58	[Current strategies in the treatment of renal-cell cancer: targeted therapies]. <i>Medicina Clínica</i> , <b>2008</b> , 130, 380-92	1	2
57	Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. <i>Urology</i> , <b>2008</b> , 72, 898-902	1.6	10
56	Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. <i>European Urology Supplements</i> , <b>2008</b> , 7, 36-45	0.9	5
55	A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. <i>Journal of Urology</i> , <b>2008</b> , 180, 867-72; discussion 872	2.5	50
54	Systemic therapy for metastatic renal cell carcinoma. <i>Urologic Clinics of North America</i> , <b>2008</b> , 35, 687-701; ix	2.9	28
53	The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2008</b> , 31, 417-23	2.7	6
52	Paralytic Ileus Associated with Capecitabine. <i>Tumori</i> , <b>2008</b> , 94, 742-745	1.7	1
51	Gemcitabine and Capecitabine (GemCap) Regimen for Solid Tumors. <i>Hospital Pharmacy</i> , <b>2009</b> , 44, 303-309	1	1
50	The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. <i>Medical Oncology</i> , <b>2009</b> , 26 Suppl 1, 3-12	3.7	14
49	Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 45-51	3.5	4

48	Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma. <i>International Journal of Urology</i> , <b>2009</b> , 16, 576-9	2.3	5
47	Renal cell carcinoma. <i>Lancet, The</i> , <b>2009</b> , 373, 1119-32	4.0	1078
46	A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2009</b> , 32, 453-9	2.7	15
45	The end of chemotherapy in renal cell carcinoma: for much but not for all. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 522-3	2.7	
44	Renal cell cancer: state of the art in adjuvant therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2010</b> , 5, 242-50	2.6	1
43	Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. <i>European Journal of Medical Research</i> , <b>2010</b> , 15, 287-91	4.8	25
42	Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5022-9	2.2	22
41	Another step toward the cure of metastatic renal cell carcinoma?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5017-9	2.2	13
40	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 350-7	21.7	61
39	New targeted therapies for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 933-45.9		1
38	A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 443-8	2.7	9
37	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. <i>BJU International</i> , <b>2011</b> , 107, 741-747	5.6	25
36	Systemic therapy for sarcomatoid renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 913-20	3.5	7
35	Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e203-5	2.2	15
34	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. <i>EPMA Journal</i> , <b>2011</b> , 3, 1	8.8	12
33	Kidney Cancer. <b>2012</b> ,		4
32	Systemic adjuvant therapies in renal cell carcinoma. <i>Oncology Reviews</i> , <b>2012</b> , 6, e18	4.3	6
31	Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer, Supplement</i> , <b>2013</b> , 11, 160-8	1.6	2

30	Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2013</b> , 36, 450-4	2.7	7
29	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 535-54	2.4	58
28	The role of inflammation in kidney cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 816, 197-234	3.6	62
27	First-Generation Tyrosine Kinase Inhibitors: Clinical Results. <b>2015</b> , 177-205		1
26	Kidney Cancer. <b>2015</b> ,		1
25	Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 518-26	7	33
24	Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. <i>European Urology</i> , <b>2015</b> , 67, 740-9	10.2	129
23	Capecitabine for treating head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 851-9	5.9	6
22	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 804-834	7.3	320
21	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 163-170	5.9	4
20	Highly functionalized piperidines: Free radical scavenging, anticancer activity, DNA interaction and correlation with biological activity. <i>Journal of Advanced Research</i> , <b>2018</b> , 9, 51-61	13	25
19	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	11
18	A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy. <i>Translational Andrology and Urology</i> , <b>2019</b> , 8, 339-345	2.3	1
17	Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma. <i>Cancer Medicine</i> , <b>2019</b> , 8, 4304-4314	4.8	5
16	Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma and Display No Significant Systemic Toxicity. <i>ACS Pharmacology and Translational Science</i> , <b>2020</b> , 3, 644-654	5.9	6
15	Management of Patients with Pathologic Variants of Renal Cell Carcinoma: Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid Differentiation. <b>2008</b> , 529-544		1
14	Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma. <b>2012</b> , 225-239		1
13	Treatment of Advanced Renal Cell Carcinoma. <b>2012</b> , 1475-1491.e5		2

12	A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 150-4	2.7	11
11	Management of metastatic renal cell carcinoma - mini review. <i>Journal of Kidney Cancer and VHL</i> , <b>2015</b> , 2, 75-83	1.4	4
10	Cancer of the Kidney. <b>2008</b> , 1613-1634		
9	Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations. <b>2012</b> , 249-264		
8	Renal Neoplasia. <b>2012</b> , 1508-1535		
7	Chemotherapy, Targeted Therapies, and Biological Therapies for Renal Cell Carcinoma. <b>2013</b> , 713-725		
6	Cancer of the Kidney. <b>2014</b> , 1416-1444.e5		1
5	Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma. <b>2015</b> , 315-334		
4	Variant Renal Carcinoma Histologies: Therapeutic Considerations. <b>2015</b> , 345-364		
3	Perioperative Considerations in Metastatic Renal Cell Carcinoma. <i>Reviews in Urology</i> , <b>2016</b> , 18, 133-142	1	
2	Encapsulation of Gold-Based Anticancer Agents in Protease-Degradable Peptide Nanofilaments Enhances Their Potency.		0
1	Inflammation in Urological Malignancies: The Silent Killer. <b>2023</b> , 24, 866		0